A5074389534- Acute Myeloid Leukemia Research
- Peptidase Inhibition and Analysis
- Immunotherapy and Immune Responses
- Multiple Myeloma Research and Treatments
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Mesenchymal stem cell research
- RNA Interference and Gene Delivery
- Protein Degradation and Inhibitors
Nanjing Drum Tower Hospital
2017-2018
Nanjing Medical University
2017-2018
DOX/GA–CdTe–CD22 can precisely target lymphoma and deliver DOX GA to cells improve their therapeutic effects.
Abstract Rationale: Philadelphia chromosome positive acute myeloid leukemia (Ph+ AML) is a rare subtype of AML that now included as provisional entity in the 2016 revised WHO classification malignancies. However, clear distinction between de novo Ph+ and chronic blast crisis challenging. It still matter debate whether patients should be treated with chemotherapy or tyrosine kinase inhibitors first-line therapy. Patient concerns: We reported here case 46-year-old man who was diagnosed AML....